Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hertz, Daniel L
836  Ergebnisse:
Personensuche X
?
1

Paclitaxel therapeutic drug monitoring - International asso..:

Hertz, Daniel L. ; Joerger, Markus ; Bang, Yung-Jue...
European Journal of Cancer.  202 (2024)  - p. 114024 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Pharmacogenetic and clinical risk factors for bevacizumab-r..:

Patel, Jai N. ; Jiang, Chen ; Owzar, Kouros...
The Pharmacogenomics Journal.  24 (2024)  2 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
3

Incorporation of emergent symptoms and genetic covariates i..:

Rattsev, Ilia ; Stearns, Vered ; Blackford, Amanda L...
JAMIA Open.  7 (2024)  1 - p. , 2024
Link: https://doi.org/10.1093/..
 
?
4

Attempted replication of pharmacogenetic association of var..:

Liang, Yuqing ; Gersch, Christina L. ; Lehman, Jennifer...
Pharmacogenetics and Genomics.  34 (2024)  4 - p. 126-129 , 2024
Link: https://doi.org/10.1097/..
 
?
5

Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations..:

Mc Laughlin, Anna M. ; Helland, Thomas ; Klima, Fenja...
Clinical Pharmacology & Therapeutics.  , 2024
Link: https://doi.org/10.1002/..
 
?
6

Recommendations for pharmacogenetic testing in clinical pra..:

Hertz, Daniel L ; Bousman, Chad A ; McLeod, Howard L...
American Journal of Health-System Pharmacy.  , 2024
Link: https://doi.org/10.1093/..
 
?
7

Using maximum plasma concentration (Cmax) to personalize ta..:

Sun, Yuchen ; Cheng, Yue ; Hertz, Daniel L.
Cancer Chemotherapy and Pharmacology.  , 2024
Link: https://doi.org/10.1007/..
 
?
8

Evolution of predictive risk factor analysis for chemothera..:

Hertz, Daniel L. ; Lustberg, Maryam B ; Sonis, Stephen
Supportive Care in Cancer.  31 (2023)  10 - p. , 2023
Link: https://doi.org/10.1007/..
 
?
9

Patient perceptions of altering chemotherapy treatment due ..:

Hertz, Daniel L ; Tofthagen, Cindy ; Rossi, Emanuela...
Supportive Care in Cancer.  32 (2023)  1 - p. , 2023
Link: https://doi.org/10.1007/..
 
?
10

Confirmatory DPYD Testing in Patients Receiving Fluoropyrim..:

Pasternak, Amy L. ; Seda, Robinson ; Lipa, Joseph...
Clinical Pharmacology & Therapeutics.  114 (2023)  2 - p. 356-361 , 2023
Link: https://doi.org/10.1002/..
 
?
11

Risk of Toxicity From Topical 5‐Fluorouracil Treatment in P..:

Granados, Javier ; Pasternak, Amy L. ; Henry, N. Lynn..
Clinical Pharmacology & Therapeutics.  115 (2023)  3 - p. 452-456 , 2023
Link: https://doi.org/10.1002/..
 
?
12

Response to the FDA Decision Regarding DPYD Testing Prior t..:

Hertz, Daniel L. ; Smith, D. Max ; Scott, Stuart A...
Clinical Pharmacology & Therapeutics.  114 (2023)  4 - p. 768-779 , 2023
Link: https://doi.org/10.1002/..
 
?
13

Wearables, sensors, and smart devices for the detection and..:

Mantovani, Elisa ; Demrozi, Florenc ; Hertz, Daniel L....
Journal of the Peripheral Nervous System.  27 (2022)  4 - p. 238-258 , 2022
Link: https://doi.org/10.1111/..
 
?
14

Impact of Pharmacogenetics on Intravenous Tacrolimus Exposu..:

Pasternak, Amy L. ; Marcath, Lauren A. ; Li, Yajing...
Transplantation and Cellular Therapy.  28 (2022)  1 - p. 19.e1-19.e7 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Co-occurrence and metabolic biomarkers of sensory and motor..:

Chen, Ciao-Sin ; Smith, Ellen M. Lavoie ; Stringer, Kathleen A...
Breast Cancer Research and Treatment.  194 (2022)  3 - p. 551-560 , 2022
Link: https://doi.org/10.1007/..
 
1-15